Drug Discovery Services Market Set to Deliver Major Revenue Shares during the Fo

Posted by Arslan on January 24th, 2019

According to a study by Fact.MR, the global market for drug discovery services is likely to experience strong growth. By 2026 end, the global market for drug discovery services is also estimated to bring in US$ 16,800.1 million revenue. Advancements in the drug discovery technologies are leading to the better drug discovery services. Some of the upcoming trends in the market in terms of drug discovery technology are regulatory initiatives towards pharmacogenomics technology, combinatorial chemistry technology, etc. there has also been an increase in the adoption of label-free techniques.

Considering the wide scope of the global drug discovery services market, the report by Fact.MR offers in-depth analysis, segment-wise analysis and forecast. The global drug discovery services market is segmented on the basis of process, type, drug type, therapeutic area, and region. This segmentation also includes country-wise analysis considering all the key parameters of the global drug discovery services market.

North America is likely to remain dominant in the global drug discovery services market throughout the forecast period 2017-2026. Presence of leading pharmaceutical companies in the region is one of the factors driving the growth of drug discovery services in North America.

Asia Pacific Excluding Japan (APEJ) is also anticipated to witness significant growth during 2017-2026. India and China are slowly becoming preferred locations for drug discovery outsourcing due to the technological capabilities developed. Fewer regulations and low manufacturing costs are also fueling the growth in APEJ region.

Browse Full Report on Drug Discovery Services Market with TOC-

https://www.factmr.com/report/375/drug-discovery-services-market

The report’s succeeding section focuses on drivers, restraints and key trends from macroeconomic, demand, and supply perspectives. Impact analysis of weighted average model-based growth drivers is contained in the report for better provision of decision-making insights to clients.

Hit-To-Lead Identification to Gain Maximum Traction 

Compared to the various processes in the drug discovery services, Hit-To-Lead identification is anticipated to gain maximum traction. Hit-To-Lead identification is likely to exceed US$ 6,900 million revenue towards 2026 end. Increasing research based on the High-Throughput Screening (HTS) is the main factor driving the use of hit-to-lead identification process.

Medicinal Chemistry to be the Largest Type of Drug Discovery Services

Medicinal chemistry is projected to emerge as the largest type in the drug discovery services market. Medicinal chemistry is estimated to bring in close to US$ 6,100 million revenue. There has been an increase in the outsourcing by pharmaceutical companies, this is emerging as the driving factor. Many drug discovery services providers based in Asia are increasing their foothold in North America and Europe.

The report offers a profile of some prominent players in the global drug discovery services market, which will stay active through 2026. The leading companies are Thermo Fisher Scientific, Inc., Merck Millipore, GE Healthcare, Albany Molecular Research, Inc. (AMRI), Charles River Laboratories International, Evotec, Pharmaceutical Product Development, LLC. (Ppd), Covance, Jubilant Biosys, Genscript Biotech Corporation, Aurigene Discovery Technologies, Wuxi Apptec, and Syngene.